Cutaneous Lupus Erythematosus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cutaneous lupus erythematosus markets reached a value of US$ 227.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 373.7 Million by 2034, exhibiting a growth rate (CAGR) of 4.63% during 2024-2034.
The cutaneous lupus erythematosus market has been comprehensively analyzed in IMARC's new report titled "Cutaneous Lupus Erythematosus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cutaneous lupus erythematosus (CLE) refers to a form of lupus that predominantly affects the skin, leading to various dermatological manifestations without necessarily affecting internal organs. The hallmark symptom of this condition is a skin rash, which can present in various forms, including butterfly-shaped facial rash (malar rash), discoid lesions (coin-shaped red patches with a scaly texture), and photosensitivity (skin sensitivity to sunlight). The rash can be painful and itchy and may lead to discoloration, affecting a patient's quality of life. Numerous other common indications include oral ulcers and hair loss. Diagnosing CLE can be challenging as it shares clinical features with various other skin disorders. A comprehensive evaluation by a dermatologist or rheumatologist is essential. Diagnosis generally involves a thorough medical history, physical examination, and skin biopsy to confirm the presence of characteristic skin changes and rule out various other conditions. Blood tests, such as antinuclear antibody (ANA) and specific autoantibody tests, may also aid in diagnosis and assessing potential systemic involvement.
The increasing cases of autoimmune disease, in which the immune system mistakenly attacks healthy skin cells and tissues, are primarily driving the cutaneous lupus erythematosus market. In addition to this, the inflating utilization of effective medications, such as antimalarials, corticosteroids, and immunosuppressive agents is also creating a positive outlook for the market. These drugs help to manage symptoms, alleviate inflammation, and prevent flare-ups in individuals suffering from the illness. Moreover, the widespread adoption of phototherapy, using ultraviolet A or B light waves to reduce disease activity, is further bolstering the market growth. Apart from this, the rising awareness about the condition and advancements in diagnostic procedures like skin biopsies and serological tests that are facilitating earlier and more accurate diagnoses are acting as another significant growth-inducing factor. Additionally, the emerging popularity of topical treatments, such as calcineurin inhibitors on account of their targeted approach and fewer systemic side effects in patients is also augmenting the market growth. Furthermore, the escalating demand for biologic therapies, which aim to target specific components of the immune system to treat severe or treatment-resistant cases of CLE, is expected to drive the cutaneous lupus erythematosus market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cutaneous lupus erythematosus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cutaneous lupus erythematosus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cutaneous lupus erythematosus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cutaneous lupus erythematosus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cutaneous lupus erythematosus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cutaneous lupus erythematosus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cutaneous lupus erythematosus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cutaneous lupus erythematosus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cutaneous lupus erythematosus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus across the seven major markets?
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by type across the seven major markets?
How many patients are diagnosed (2018-2034) with cutaneous lupus erythematosus across the seven major markets?
What is the size of the cutaneous lupus erythematosus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cutaneous lupus erythematosus?
What will be the growth rate of patients across the seven major markets?
Cutaneous Lupus Erythematosus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cutaneous lupus erythematosus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cutaneous lupus erythematosus market?
What are the key regulatory events related to the cutaneous lupus erythematosus market?
What is the structure of clinical trial landscape by status related to the cutaneous lupus erythematosus market?
What is the structure of clinical trial landscape by phase related to the cutaneous lupus erythematosus market?
What is the structure of clinical trial landscape by route of administration related to the cutaneous lupus erythematosus market?
The cutaneous lupus erythematosus market has been comprehensively analyzed in IMARC's new report titled "Cutaneous Lupus Erythematosus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cutaneous lupus erythematosus (CLE) refers to a form of lupus that predominantly affects the skin, leading to various dermatological manifestations without necessarily affecting internal organs. The hallmark symptom of this condition is a skin rash, which can present in various forms, including butterfly-shaped facial rash (malar rash), discoid lesions (coin-shaped red patches with a scaly texture), and photosensitivity (skin sensitivity to sunlight). The rash can be painful and itchy and may lead to discoloration, affecting a patient's quality of life. Numerous other common indications include oral ulcers and hair loss. Diagnosing CLE can be challenging as it shares clinical features with various other skin disorders. A comprehensive evaluation by a dermatologist or rheumatologist is essential. Diagnosis generally involves a thorough medical history, physical examination, and skin biopsy to confirm the presence of characteristic skin changes and rule out various other conditions. Blood tests, such as antinuclear antibody (ANA) and specific autoantibody tests, may also aid in diagnosis and assessing potential systemic involvement.
The increasing cases of autoimmune disease, in which the immune system mistakenly attacks healthy skin cells and tissues, are primarily driving the cutaneous lupus erythematosus market. In addition to this, the inflating utilization of effective medications, such as antimalarials, corticosteroids, and immunosuppressive agents is also creating a positive outlook for the market. These drugs help to manage symptoms, alleviate inflammation, and prevent flare-ups in individuals suffering from the illness. Moreover, the widespread adoption of phototherapy, using ultraviolet A or B light waves to reduce disease activity, is further bolstering the market growth. Apart from this, the rising awareness about the condition and advancements in diagnostic procedures like skin biopsies and serological tests that are facilitating earlier and more accurate diagnoses are acting as another significant growth-inducing factor. Additionally, the emerging popularity of topical treatments, such as calcineurin inhibitors on account of their targeted approach and fewer systemic side effects in patients is also augmenting the market growth. Furthermore, the escalating demand for biologic therapies, which aim to target specific components of the immune system to treat severe or treatment-resistant cases of CLE, is expected to drive the cutaneous lupus erythematosus market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cutaneous lupus erythematosus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cutaneous lupus erythematosus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cutaneous lupus erythematosus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cutaneous lupus erythematosus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cutaneous lupus erythematosus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cutaneous lupus erythematosus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the cutaneous lupus erythematosus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cutaneous lupus erythematosus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cutaneous lupus erythematosus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus across the seven major markets?
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of cutaneous lupus erythematosus by type across the seven major markets?
How many patients are diagnosed (2018-2034) with cutaneous lupus erythematosus across the seven major markets?
What is the size of the cutaneous lupus erythematosus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cutaneous lupus erythematosus?
What will be the growth rate of patients across the seven major markets?
Cutaneous Lupus Erythematosus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cutaneous lupus erythematosus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cutaneous lupus erythematosus market?
What are the key regulatory events related to the cutaneous lupus erythematosus market?
What is the structure of clinical trial landscape by status related to the cutaneous lupus erythematosus market?
What is the structure of clinical trial landscape by phase related to the cutaneous lupus erythematosus market?
What is the structure of clinical trial landscape by route of administration related to the cutaneous lupus erythematosus market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CUTANEOUS LUPUS ERYTHEMATOSUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CUTANEOUS LUPUS ERYTHEMATOSUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CUTANEOUS LUPUS ERYTHEMATOSUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 CUTANEOUS LUPUS ERYTHEMATOSUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CUTANEOUS LUPUS ERYTHEMATOSUS - UNMET NEEDS
10 CUTANEOUS LUPUS ERYTHEMATOSUS - KEY ENDPOINTS OF TREATMENT
11 CUTANEOUS LUPUS ERYTHEMATOSUS - MARKETED PRODUCTS
11.1 List of Cutaneous Lupus Erythematosus Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CUTANEOUS LUPUS ERYTHEMATOSUS - PIPELINE DRUGS
12.1 List of Cutaneous Lupus Erythematosus Pipeline Drugs Across the Top 7 Markets
12.1.1 Edecesertib - Gilead Sciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BIIB059 (litifilimab) - Biogen
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 M5049 - Merck
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 CUTANEOUS LUPUS ERYTHEMATOSUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CUTANEOUS LUPUS ERYTHEMATOSUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CUTANEOUS LUPUS ERYTHEMATOSUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cutaneous Lupus Erythematosus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cutaneous Lupus Erythematosus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cutaneous Lupus Erythematosus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cutaneous Lupus Erythematosus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cutaneous Lupus Erythematosus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cutaneous Lupus Erythematosus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cutaneous Lupus Erythematosus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cutaneous Lupus Erythematosus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
16 CUTANEOUS LUPUS ERYTHEMATOSUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CUTANEOUS LUPUS ERYTHEMATOSUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CUTANEOUS LUPUS ERYTHEMATOSUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CUTANEOUS LUPUS ERYTHEMATOSUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CUTANEOUS LUPUS ERYTHEMATOSUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CUTANEOUS LUPUS ERYTHEMATOSUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 CUTANEOUS LUPUS ERYTHEMATOSUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CUTANEOUS LUPUS ERYTHEMATOSUS - UNMET NEEDS
10 CUTANEOUS LUPUS ERYTHEMATOSUS - KEY ENDPOINTS OF TREATMENT
11 CUTANEOUS LUPUS ERYTHEMATOSUS - MARKETED PRODUCTS
11.1 List of Cutaneous Lupus Erythematosus Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CUTANEOUS LUPUS ERYTHEMATOSUS - PIPELINE DRUGS
12.1 List of Cutaneous Lupus Erythematosus Pipeline Drugs Across the Top 7 Markets
12.1.1 Edecesertib - Gilead Sciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BIIB059 (litifilimab) - Biogen
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 M5049 - Merck
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 CUTANEOUS LUPUS ERYTHEMATOSUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CUTANEOUS LUPUS ERYTHEMATOSUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CUTANEOUS LUPUS ERYTHEMATOSUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cutaneous Lupus Erythematosus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cutaneous Lupus Erythematosus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cutaneous Lupus Erythematosus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cutaneous Lupus Erythematosus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cutaneous Lupus Erythematosus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cutaneous Lupus Erythematosus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cutaneous Lupus Erythematosus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cutaneous Lupus Erythematosus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cutaneous Lupus Erythematosus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cutaneous Lupus Erythematosus - Access and Reimbursement Overview
16 CUTANEOUS LUPUS ERYTHEMATOSUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CUTANEOUS LUPUS ERYTHEMATOSUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CUTANEOUS LUPUS ERYTHEMATOSUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
